Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company leveraging artificial intelligence, has scheduled a webcast to present its second-quarter 2026 operating and financial results. The event is set for Aug. 14, 2026, at 9 a.m. ET. President and CEO Panna Sharma, along with members of the management team, will review the quarter ended June 30, 2026, and discuss upcoming milestones, clinical trials, and developments involving the company’s RADR® and Open-Medicine AI platforms. A replay will be accessible through the investor relations section of Lantern Pharma’s website following the event.
The announcement comes as Lantern Pharma continues to advance its AI-driven approach to oncology drug development. The company’s proprietary RADR® platform uses machine learning to analyze vast datasets, aiming to improve the efficiency and success rates of cancer therapies. The webcast is expected to provide insights into how these technologies are being applied across its pipeline and commercial initiatives.
Lantern Pharma’s clinical pipeline includes LP-184, an acylfulvene derivative, and LP-284, a compound targeting TC-NER in hematologic and solid tumors. Additionally, LP-300, a cisplatin/ethacraplatin analog, is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. The company is also developing LP-184 for pediatric CNS cancers through Starlight Therapeutics, its wholly owned subsidiary focused on central nervous system malignancies.
A significant development is the commercial availability of withZeta.ai, Lantern’s multi-agentic AI co-scientist platform. Now offered as a subscription-based research tool, withZeta.ai is designed for the global biomedical and drug development community. This marks a new revenue stream for the company, potentially broadening its financial base beyond traditional drug development milestones. The platform’s launch aligns with Lantern’s strategy to monetize its AI capabilities, which could have implications for the broader pharmaceutical industry by providing researchers with advanced tools for drug discovery and development.
The webcast will likely address the progress of these clinical programs and the adoption of withZeta.ai. Investors and industry observers will be keen to hear updates on trial enrollment, data readouts, and any strategic partnerships that may arise from the AI platform’s commercial rollout. The company’s emphasis on AI-driven precision oncology positions it at the intersection of two rapidly evolving fields: artificial intelligence and cancer therapeutics.
Lantern Pharma operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The company’s newsroom provides ongoing updates on its activities, and the full press release for this announcement can be accessed at https://ibn.fm/l80kv. As the webcast approaches, stakeholders will be watching for details on how the company plans to leverage its AI assets to advance its pipeline and generate sustainable growth.
